News
ATRS
--
0.00%
--
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Zacks · 3d ago
Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition
MT Newswires · 05/12 09:58
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.
Zacks · 04/26 17:20
Halozyme Reports Tender Offer To Buy All Shares Of Antares Pharma At $5.60/Share In Cash
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to
Benzinga · 04/26 12:15
Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares
MT Newswires · 04/26 10:29
Analysts Are Downgrading These 10 Pharmaceutical Stocks
In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. You can skip our analysis of the pharmaceutical industry and go directly to Analysts Are Downgrading These 5 Pharmaceutical Stocks. The pharmaceutical industry ...
Insider Monkey · 04/20 13:17
Antares Pharma downgraded by Raymond James, 4 others after Halozyme ~$1B acquisition offer
Antares Pharma (NASDAQ:ATRS) was downgraded by five firms — Truist, Ladenburg, Raymond James, Piper Sandler and H.C. Wainwright — after Halozyme Therapeutics (HALO) said on April 13 that it was acquiring
Seekingalpha · 04/14 14:58
Halozyme (HALO) to Acquire Antares for Auto Injector Platform
Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.
Zacks · 04/14 14:06
Looking Into Antares Pharma Inc's Recent Short Interest
Antares Pharma Inc's (NASDAQ:ATRS) short percent of float has risen 8.8% since its last report. The company recently reported that it has 4.49 million shares sold short, which is 2.72% of all regular shares that are available for trading.
Benzinga · 04/14 13:14
Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?
Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks · 04/14 10:26
--Ladenburg Thalmann Downgrades Antares Pharma to Neutral From Buy
MT Newswires · 04/14 08:01
--HC Wainwright Downgrades Antares Pharma to Neutral From Buy; Price Target is $5.60
MT Newswires · 04/14 06:14
--Piper Sandler Downgrades Antares Pharma to Neutral From Overweight, Adjusts Price Target to $5.60 From $6
MT Newswires · 04/14 05:23
Raymond James Downgrades Antares Pharma to Market Perform From Strong Buy
MT Newswires · 04/14 05:20
10 Hottest Stocks to Watch on Wednesday
In this article, we will discuss some of the popular stocks trending today. To take a look at some more stocks that are in the news, go to 5 Hottest Stocks to Watch on Wednesday. The US stock market is in the green today, with investors absorbing the earni...
Insider Monkey · 04/13 20:44
Antares Pharma to be acquired by Halozyme in $960M deal
Antares, which was originally founded in Exton, is a specialty pharmaceutical company that develops, manufactures and commercializes therapeutic products using its advanced drug delivery systems.
American City Business Journals · 04/13 18:09
ATER, HNRG and AGLE among mid-day movers
Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy
Seekingalpha · 04/13 16:55
Why Is Sierra Oncology (SRRA) Stock Up Today?
Investor Place · 04/13 15:42
Why Is BriaCell (BCTX) Stock Moving Today?
Investor Place · 04/13 14:34
Why Is Antares Pharma (ATRS) Stock Up Today?
Investor Place · 04/13 14:15
Webull provides a variety of real-time ATRS stock news. You can receive the latest news about Antares Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATRS
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products and technologies. The Company develops, manufactures, and commercialize, for itself or with partners, therapeutic products using its drug delivery systems. The Company products include XYOSTED, NOCDURNA, Epinephrine Injection USP, Sumatriptan Injection USP, Makena and Teriparatide Injection. Its XYOSTED injection product for subcutaneous administration of testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. NOCDURNA is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate. Its Epinephrine Injection USP products is indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients.